Table 1

Survival rates in TAK according to specific disease features

Study identification	N	Studied groups (follow-up duration)	Survival rates	P value	RoB QUIPS tool
Ishikawa and Maetani18	120	According to prognostic score classification. Stage 1 vs 2 vs 3. (median 13 years and 2 months)	100% vs 83.6% vs 43%	<0.001	Moderate
Ishikawa15	81	I+IIa vs IIb+III†. At 5 years and 10 years. (mean 7.4±5.8 years)	100% vs 74.2%	<0.005	Moderate
Soto et al 22	94	Patients with coronary disease developing between 10 and 19 years vs between 20 and 39 years at 2, 5 and 10 years.	50% at each time point vs 88% at each time point	–	High
Soto et al 22	94	Patients with hypertension developing between 10 and 19 years vs between 20 and 39 years at 2, 5 and 10 years. (mean 75±83 months)	65% vs 87% 57% vs 87% 48% vs 87%	–	High

*Stages defined according to the presence or absence of three predictors, major complications, progressive disease course or low ESR (<20 mm/hour): stage 1 (0 predictor or only progressive disease or only low ESR), stage 2 (only major complication or progressive disease course and low ESR or major complication and low ESR) and stage 3 (major complication and progressive course or the 3 predictors).
†(I) with or without involvement of the pulmonary artery, but all patients had narrowing or occlusion in some region of the aorta or its main branches, or both; (II) one of the following: Takayasu’s retinopathy, secondary hypertension, aortic regurgitation, or aortic or arterial aneurysm; if mild or moderate complications (IIa), if severe complications (IIb); (III) two or more of the four complications mentioned above.
ESR, erythrocyte sedimentation rate; QUIPS, Quality in Prognosis Studies tool; RoB, risk of bias; TAK, Takayasu arteritis.